title: Desensitization of functional µ-opioid receptors increases agonist off-rate.
abstract: Desensitization of µ-opioid receptors (MORs) develops over 5-15 minutes after the application of some, but not all, opioid agonists and lasts for tens of minutes after agonist removal. The decrease in function is receptor selective (homologous) and could result from 1) a reduction in receptor number or 2) a decrease in receptor coupling. The present investigation used photolysis of two caged opioid ligands to examine the kinetics of MOR-induced potassium conductance before and after MOR desensitization. Photolysis of a caged antagonist, carboxynitroveratryl-naloxone (caged naloxone), blocked the current induced by a series of agonists, and the time constant of decline was significantly decreased after desensitization. The increase in the rate of current decay was not observed after partial blockade of receptors with the irreversible antagonist, β-chlornaltrexamine (β-CNA). The time constant of current decay after desensitization was never more rapid than 1 second, suggesting an increased agonist off-rate rather than an increase in the rate of channel closure downstream of the receptor. The rate of G protein-coupled K(+) channel (GIRK) current activation was examined using photolysis of a caged agonist, carboxynitrobenzyl-tyrosine-[Leu(5)]-enkephalin. After acute desensitization or partial irreversible block of MORs with β-CNA, there was an increase in the time it took to reach a peak current. The decrease in the rate of agonist-induced GIRK conductance was receptor selective and dependent on receptor number. The results indicate that opioid receptor desensitization reduced the number of functional receptor and that the remaining active receptors have a reduced agonist affinity.
authors.affiliation: Vollum Institute, Oregon Health and Science University, Portland, Oregon williamj@ohsu.edu.
authors.forename: John T
authors.initials: JT
authors.lastname: Williams
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004745:Enkephalins / Q000494:pharmacology; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels / Q000378:metabolism; D007700:Kinetics; D008024:Ligands; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D010782:Photolysis; D011188:Potassium / Q000378:metabolism; D051381:Rats; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000701:Analgesics, Opioid; D004745:Enkephalins; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D008024:Ligands; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009271:Naltrexone; C017120:chlornaltrexamine; D011188:Potassium
references.citation: J Recept Signal Transduct Res. 2010 Oct;30(5):304-12
references.pmid: 20836728
references.citation: Mol Pharmacol. 2012 Nov;82(5):983-92
references.pmid: 22914548
references.citation: J Neurosci. 2011 Mar 23;31(12):4434-43
references.pmid: 21430144
references.citation: FASEB J. 2008 Aug;22(8):2920-7
references.pmid: 18434433
references.citation: Biochem Pharmacol. 2002 Jul 15;64(2):257-66
references.pmid: 12123746
references.citation: Mol Pharmacol. 2013 Nov;84(5):687-95
references.pmid: 23960100
references.citation: Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):19977-82
references.pmid: 23169654
references.citation: J Physiol. 2002 Dec 1;545(2):355-73
references.pmid: 12456817
references.citation: Sci Signal. 2011 Aug 9;4(185):ra52
references.pmid: 21868358
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18706-11
references.pmid: 16352729
references.citation: J Neurosci. 2006 Nov 29;26(48):12602-8
references.pmid: 17135422
references.citation: Mol Pharmacol. 1988 Apr;33(4):423-31
references.pmid: 2833686
references.citation: Mol Pharmacol. 1997 Jul;52(1):136-43
references.pmid: 9224823
references.citation: J Neurosci. 2013 Feb 27;33(9):4118-27
references.pmid: 23447620
references.citation: Br J Pharmacol. 1995 Jul;115(6):925-32
references.pmid: 7582522
references.citation: J Neurosci. 2009 Jun 3;29(22):7341-8
references.pmid: 19494155
references.citation: J Biol Chem. 1984 Nov 10;259(21):13298-303
references.pmid: 6092373
references.citation: Pharmacol Rev. 2013 Jan 15;65(1):223-54
references.pmid: 23321159
references.citation: J Biol Chem. 2007 Jun 29;282(26):19203-16
references.pmid: 17420253
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 1:S125-32
references.pmid: 18193071
references.citation: Neuron. 2006 Sep 7;51(5):561-73
references.pmid: 16950155
references.citation: J Neurosci. 1996 Feb 15;16(4):1479-85
references.pmid: 8778299
references.citation: Eur J Neurosci. 2012 Dec;36(12):3636-42
references.pmid: 23002724
references.citation: Mol Pharmacol. 2013 Mar;83(3):633-9
references.pmid: 23239825
references.citation: Nat Chem Biol. 2011 Aug 28;7(10):740-7
references.pmid: 21873996
references.citation: Neuron. 2012 Jan 26;73(2):249-59
references.pmid: 22284180
references.citation: Mol Pharmacol. 1984 Nov;26(3):489-97
references.pmid: 6092898